

Sanofi, Wednesday August 31, 2022, 07.30-08.30, Hall Porto

Olipudase alfa: a new treatment for patients with ASMD

Chair: Eugen Mengel, Hochheim, Germany

Welcome and introduction

Eugen Mengel, Hochheim, Germany

Sphingomyelin accumulation – Pathology behind the disease: sphingomyelin accumulation and clinical manifestations

Nathalie Guffon, Bron, France

Olipudase alfa data – Investigating olipudase alfa in clinical trials: efficacy and safety

Maurizio Scarpa, Udine, Italy

ASMD/olipudase alfa clinical case – The treatment outcome: an ASMD patient case study

Eugen Mengel, Hochheim, Germany

Panel discussion and Q&A

All panel

Closing remarks

Eugen Mengel, Hochheim, Germany

sponsored by

sanofi